We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pharmacokinetics of Pavaverine After Intraluminal Administration

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01436981
First Posted: September 20, 2011
Last Update Posted: June 4, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Klinikum Ludwigshafen
Information provided by (Responsible Party):
Arndt-H. Kiessling, Johann Wolfgang Goethe University Hospitals
September 14, 2011
September 20, 2011
June 4, 2013
October 2012
January 2013   (Final data collection date for primary outcome measure)
Maximum plasma concentration of papaverine [ Time Frame: 4 hours ]
Serum probes will be analysed for the concentrations of papaverine.
Same as current
Complete list of historical versions of study NCT01436981 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Pharmacokinetics of Pavaverine After Intraluminal Administration
Observational Study on Papaverine During Cardiac Surgical Procedures
The purpose of this study is to determine the pharmacokinetic of papaverine after administration into the artery mammaria interna.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
CABG patients
  • Injury of Internal Mammary Artery
  • Complications Due to Coronary Artery Bypass Graft
Procedure: CABG
Preparation of artery mammaria interna
Other Name: Paveron N
CABG with papaverine
Patients with CABG procedure
Intervention: Procedure: CABG
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
12
January 2013
January 2013   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • CABG
  • Administration of papaverine into mammaria interna

Exclusion Criteria:

  • Allergy against papaverine
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT01436981
PAV002-AHK
No
Not Provided
Not Provided
Arndt-H. Kiessling, Johann Wolfgang Goethe University Hospitals
Johann Wolfgang Goethe University Hospital
Klinikum Ludwigshafen
Principal Investigator: Arndt H Kiessling, MD Johann Wolfgang Goethe University Hospital
Johann Wolfgang Goethe University Hospital
June 2013